Rheumatoid arthritis: Current clinical and research directions

Journal of Women's Health

Volumn 6, Issue 6, 1997, Pages 627-638

  Grossman, Jennifer M ^a   Brahn, Ernest ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELL ADHESION MOLECULE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GOLD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; ENVIRONMENTAL FACTOR; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL RESEARCH; MONOZYGOTIC TWINS; MORTALITY; NEPHROTOXICITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE; WORK DISABILITY;

EID: 0031439215     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1997.6.627     Document Type: Review

References (76)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315.
2. Harris ED, Jr. Clinical features of rheumatoid arthritis. In: Kelly WN, Harris ED, Jr, Sledge CB, eds. Textbook of rheumatology, 5th ed. Philadelphia: WB Saunders, 1997:898.
3. Spector TD. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1990;16:513.
4. Yelin E. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates. J Rheumatol 1996;23 (Suppl 44):47.
5. Lubeck DP. The economic impact of arthritis. Arthritis Care Res 1995;8:304.
6. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995;50 (Suppl 1):1.
7. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: A patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827.
8. Yelin E, Lubeck D, Holman H, Epstein W. The impact of rheumatoid arthritis and osteoarthritis: The activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol 1987;14:710.
9. Reisine ST, Grady KE, Goodenow C, Fifield J. Work disability among women with rheumatoid arthritis: The relative importance of disease, social, work, and family factors. Arthritis Rheum 1989;32:538.
10. Parker JC, Wright GE. The implications of depression for pain and disability in rheumatoid arthritis. Arthritis Care Res 1995;8:279.
11. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and cause of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706.
12. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26.
13. Spector TD, Da Silva JAP. Pregnancy and rheumatoid arthritis: An overview. Am J Reprod Immunol 1992; 28:222.
14. Goemaere S, Ackerman C, Goethals K, et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990;17: 1620.
15. Latman NS. Relation of menstrual cycle phase to symptoms of rheumatoid arthritis. Am J Med 1983; 74:957.
16. Grossman CJ. Interactions between the gonadal steroids and the immune system. Science 1985;227: 257.
17. Bijlsma JWJ, van den Brink HR. Estrogens and rheumatoid arthritis. Am J Reprod Immunol 1992;28: 231.
18. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the etiopathogenesis of rheumatoid arthritis. J Rheumatol 1996;23 (Suppl 44):10.
19. Wingrave SJ, Kay CR. Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Lancet 1978;1:569.
20. Vandenbrouke JP, Valkenburg HA, Boersma JW, et al. Oral contraceptives and rheumatoid arthritis: Further evidence for a preventive effect. Lancet 1982; 2:839.
21. Spector TD, Roman E, Silman AJ. The pill, parity, and rheumatoid arthritis. Arthritis Rheum 1990;33:782.
22. Hazes JMW, Dijkmans BAC, Vandenbroucke JP, de Vries RRP, Cats A. Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 1990;33: 1770.
23. Linos A, Worthington JW, O'Fallon WM, Kurland LT. Case-control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet 1983;1:1299.
24. Hernandez-Avila M, Liang MH, Willett WC, et al. Exogenous sex hormones and the risk of rheumatoid arthritis. Arthritis Rheum 1990;33:947.
25. Romieu I, Hernandez-Avila M, Liang MH. Oral contraceptives and the risk of rheumatoid arthritis: A meta-analysis of a conflicting literature. Br J Rheumatol 1989;28 (Suppl I):13.
26. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: An overview of the analytical epidemiological studies using meta-analysis. Br J Rheumatol 1989;28 (Suppl I):11.
27. Carette S, Marcoux S, Gingras S. Postmenopausal hormones and the incidence of rheumatoid arthritis. J Rheumatol 1989;16:911.
28. Vandenbroucke JP, Witteman JCM, Valkenburg HA, et al. Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. JAMA 1986;255:1299.
29. Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA, Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med 1993;329:466.
30. Harris ED, Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322:1277.
31. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Kelly WN, Harris ED, Jr, Sledge CB, eds. Textbook of rheumatology, 5th ed. Philadelphia: W.B. Saunders, 1997;851.
32. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801.
33. Roudier J, Petersen J, Rhodes GH, Luka J, Carson DA. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci USA 1989;86:5104.
34. Auger I, Roudier J. A function for the QKRAA amino acid motif mediating binding of DnaJ to DnaK. Implications for the association of rheumatoid arthritis with HLA-DR4. J Clin Invest 1997;99:1818.
35. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997; 40:598.
36. Thomas R, Lipsky PE. Presentation of self peptides by dendritic cells: Possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1996;39:183.
37. Burmester GR, Stuhlmüller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5.
38. Soden M, Rooney M, Whelan A, Feighery C, Bresnihan B. Immunohistological analysis of the synovial membrane: Search for predictors of the clinical course in rheumatoid arthritis. Ann Rheum Dis 1991;50:673.
39. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115.
40. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: Passive responders or transformed aggressors. Arthritis Rheum 1996;39:1781.
41. Mojcik CF, Shevach EM. Adhesion molecules: A rheumatologic perspective. Arthritis Rheum 1997;40: 991.
42. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713.
43. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for non-steroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996; 26:435.
44. Harris ED, Jr. Treatment of rheumatoid arthritis. In: Kelly WN, Harris ED, Jr, Sledge CB, eds. Textbook of rheumatology, 5th ed. Philadelphia: W.B. Saunders, 1997:933.
45. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723.
46. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585.
47. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494.
48. Van der Heide A, Jacobs JWG, Bijlsma JWG, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: A randomized, controlled trial. Ann Intern Med 1996;124:699.
49. Wilske KR, Healey LA. Remodeling the pyramid - A concept whose time has come. J Rheumatol 1989; 16:565.
50. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994.
51. Wilske KR. Approach to the management of rheumatoid arthritis: Rationale for early combination therapy. J Rheumatol 1993;32 (Suppl 1):24.
52. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications. N Engl J Med 1996;334:1287.
53. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137.
54. Paulus HE. History of combination therapy of rheumatoid arthritis. J Rheumatol 1996;23 (Suppl 44):38.
55. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994;37:1487.
56. Wicks I, Cooley H, Szer J. Autologous hemopoietic stem cell transplantation: A possible cure for rheumatoid arthritis. Arthritis Rheum 1997;40:1005.
57. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: A 48-week, double-blind placebo-controlled trial. Ann Intern Med 1995;122:81.
58. O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo. Arthritis Rheum 1997;40:842.
59. Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal anti-inflammatory drugs: Clinical and immune correlates. Arthritis Rheum 1995;38: 1107.
60. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med 1993;119:867.
61. Bhatt-Sanders D. Acupuncture for rheumatoid arthritis: An analysis of the literature. Semin Arthritis Rheum 1985;14:225.
62. Moreland LW, Heck LW, Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: Concepts and progress. Arthritis Rheum 1997;40:397.
63. Olsen NJ, Brooks RH, Cush JJ, et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1102.
64. Moreland LW, Pratt PN, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581.
65. 486 IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum 1993; 36:1223.
66. Isaacs JD, Manna VK, Rapson N, et al. Campath 1H in rheumatoid arthritis: An intravenous dose-ranging study. Br J Rheumatol 1996;35:231.
67. Cannon GW, Pincus SH, Emkey RD, et al. Double-blind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1989;32:964.
68. Elliott MJ, Feldmann M, Kalden JR, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105.
69. Moreland LW, Margolies G, Heck LW, Jr, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849.
70. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, The IL-1Ra arthritis study group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092.
71. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141.
72. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992.
73. Sieper J, Kary S, Sörensen H, et al. Oral type II collagen treatment in early rheumatoid arthritis: A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996;39:41.
74. Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808.
75. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992;89:4076.
76. Moreland LW, Heck LW, Jr, Koopman WJ, et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of a phase I dose escalation study. J Rheumatol 1996;23:1353.